Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia.

Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia. Abstract Text:

I Kline,M Gang,R J Woodman,R L Cysyk,J M Venditti,

Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia. Publishing Authors By Initials

I Kline,M Gang,RJ Woodman,RL Cysyk,JM Venditti,

For similar male urogenital diseases: urologic diseases: urinary bladder diseases research abstracts see: male urogenital diseases: urologic diseases: urinary bladder diseases research

PUBMED ID PMID:

MEDLINE DATE: 1973 Sep-Oct

Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer chemotherapy reports. Part 1

VOLUME: 57

Page Numbers: 299-304

Journal Abbreviation:

ISSN: 0069-0112

DAY: 20

MONTH: 02

YEAR: 2008

Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7607105

Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia. Keywords Mesh Terms:

KEYWORDS: Urinary Bladder Diseases

MESH TERMS: chemically induced

Chemical & Substance for Abstract: Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia. Information

Substance Name: Acetylcysteine

Registry Number: 616-91-1

Grant and Affiliation Information for Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Chemother Rep

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Protection with N-acetyl-L-cysteine NSC-111180 against isophosphamide NSC-109724 toxicity and enhancement of therapeutic effect in early murine L1210 leukemia Related Publications

• A Dialysis Patient with Bacteremia Caused by a Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Carrying the Staphylococcal Chromosome Cassette (SCC) mec type V.
• A manual on quantitative drug evaluation in experimental tumor systems.
• A meta-analytic approach to ilioinguinal nerve excision or preservation during open inguinal hernia repair.
• A prospective screening program: current screening and its status.
• Adenoviral-mediated correction of methylmalonyl-CoA mutase deficiency in murine fibroblasts and human hepatocytes.
• Adenovirus-Mediated Gene Delivery Rescues a Neonatal Lethal Murine Model of mut(0) Methylmalonic Acidemia.
• Antileukemic action of reserpine.
• Changes in susceptibilities to teicoplanin, vancomycin and other antibiotics among Staphylococcus aureus isolates in a tertiary-care University hospital.
• Combination radiotherapy and chemotherapy for P388 lymphocytic leukemia in vivo.
• Combination therapy studies with L-asparaginase (NSC-109229) and other antitumor agents.
• Effectiveness of antileukemic agents in mice inoculated with a leukemia L1210 variant resistant to 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196).
• Effectiveness of antileukemic agents in mice inoculated with leukemia L1210 variants resistant to 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) or 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196).
• Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
• Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
• Immunity of mice surviving systemic leukaemia (L1210) to antifolic resistant variants of the disease.
• In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
• Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscle.
• Multidrug-Resistant Acinetobacter baumannii Outbreak in an Intensive Care Unit.
• Observations on a leukemic cell variant in mice.
• Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia.
• Post-endoscopic polypectomy delayed bleeding concomitant with an abdominoperineal resection: a case report.
• Prediction of the long-term creep behaviour of hydroxyapatite-filled polyethylmethacrylate bone cements.
• Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia.
• Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
• The accumulation of reproductive barriers during speciation: postmating barriers in two behaviorally isolated species of darters (Percidae: Etheostoma).
• The efficacy and safety of maintenance ECT in geriatric patients.
• The new NCI screen and its implications for clinical evaluation.
• Upper and lower gastrointestinal diseases in liver transplant candidates.
• Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroe
• Working session report: in vivo-in vitro screening.